# EP0031

Source: https://onco.cc/drugs/ep0031/  
OnCo record `ep0031` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EP0031 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for non-small-cell lung cancer, aimed at RET.

## Summary

EP0031 is a small-molecule drug developed by Ellipses Pharma. Its target is RET (the sponsor names RET). ClinicalTrials.gov describes the intervention as: EP0031 is a potent next-generation selective RET-inhibitor (SRI). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05443126, plans to enrol 265 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: Small-molecule drug directed at RET, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of EP0031: https://clinicaltrials.gov/search?intr=EP0031
- Sponsor page: https://www.ellipses.life

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [RET](https://onco.cc/targets/ret/)
- companies: [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/)
- trials: [A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies](https://onco.cc/trials/nct05443126/)

---
JSON: https://onco.cc/api/v1/entities/ep0031.json